CORDIS
EU research results

CORDIS

English EN

PexyEazy® - an innovative surgical device for treatment of haemorrhoids.

Project information

Grant agreement ID: 878276

Status

Closed project

  • Start date

    1 September 2019

  • End date

    31 December 2019

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

DEVELOPERATION AB

Sweden

Objective

Haemorrhoids is recognized as one of the most common medical conditions in general population, effecting up to 33% of the population under the age of 50 and up to 50% of the global population over 50-years old. Haemorrhoids are swellings containing enlarged blood vessels found inside or around the bottom (the rectum and anus). They occur when the rectal mucosa falls down from its normal position, causing problems like bleeding, soiling, itching and soreness, redness and swelling. Currently available treatments like surgeries are highly invasive and are associated with postoperative pain, high frequency of relapse, stenosis (narrowing of rectum), faecal or air incontinence and long recovery time (up to 1 month). In severe cases, surgery is the only option and modern surgical treatments focus on preserving and restoring the haemorrhoids, but they are still very expensive and not affordable for almost all population affected. Developeration has developed PexyEazy®, a novel medical device aiming to revolutionize the surgical treatment of haemorrhoids. The single-use, small (<26mm in diameter) device is based on a well-documented treatment method called mucopexy by which the haemorrhoid is lifted back to its normal position by applying running sutures in the mucosa above the haemorrhoid. This reduces the swelling of the haemorrhoid and the symptoms disappear. With PexyEazy®, haemorrhoid operations can be performed without the requirement of general anaesthesia, with less postoperative complications and in only 10 minutes, resulting in significant cost savings of 70% each procedure. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project, Developeration AB will conduct clinical trials with hospitals in Sweden, where they will initially market their product, along with scaling up for commercialization.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

DEVELOPERATION AB

Address

Kottgatan 213
122 64 Enskede

Sweden

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 50 000

Project information

Grant agreement ID: 878276

Status

Closed project

  • Start date

    1 September 2019

  • End date

    31 December 2019

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

DEVELOPERATION AB

Sweden